

ABSTRACT TEMPLATE for Company Presentations

Questions for categories: Biotech/Pharma or Medical Devices or Health IT/Digital

- **Investment Rational**

Precise Bio is a bioconvergence company in the tissue engineering field focusing initially in ophthalmology, targeting indications that will replace donor tissue transplant and unmet therapeutic needs that can be solved by tissue transplant. The relevant markets are over \$1B segments in several indications. Precise was founded by Dr. Anthony Atala and Prof. Shay Soker from Wake Forest Institute of Regenerative Medicine, world leaders in the field of RegenMed and Aryeh Batt the developer of the Printing technology and CEO of the company.

- **Business Strategy**

Precise has established an Ophthalmology BU and is collaborating with leaders in the field both in R&D and commercializing efforts. The Cornea graft shall be commercialized via the eye-banks and utilize existing sales and distribution channels..

- **Core Technology**

Precise 4D bio fabrication technology is comprised from the unique patented 3D printing technology enabling engineering of vital and functional tissue, together with cell biology, bio materials, engineering process and a multi-disciplinary combination of the technology components

- **Product Profile/Pipeline**

The company has 3 products in preclinical stage. Corneal graft for EK, lenticules for Keratoconus and vision correction and Retina tissue addressing AMD. The current focus is in the ophthalmology field and precise is building a pipeline of products addressing multibillion unmet therapeutic need in this field. In the future precise will be addressing additional fields as cardiology, orthopedics and others utilizing Precise's platform technologies and translating them to clinical worthy tissues and organs .

- **What's Next?**

Precise is targeting clinical studies in 2023.
Precise has raised \$21M in 3 rounds and is currently raising additional \$25M targeting to take us through initial clinical results